Thursday, June 15, 2017 8:12:30 AM
In October 2013 we had to cease trialing the process due to lack of
available and sustainable funds. The new initiative to generate investment into the company will allow us to
recommence these trials and move towards selling the product on the open market. As a result, the Company is still in
development and approval stage.
In February 2014 we appointed an IR company who are looking to raise the estimated $2million required to obtain
FDA approval of the patented process to make the product available to our targeted markets.
https://www.otcmarkets.com/financialReportViewer?symbol=TCEL&id=117970
Now jump forward to June 2015,which is the last update!
COMPANY STATEMENT
FROM: JOHN MEREDITH, CFO & DIRECTOR, Therapy Cells, Inc
We have been actively engaged in negotiations regarding the required funding for the Company as stated in the last quarterly Financial Statements posted on the OTC website. Whilst those negotiations have been successfully concluded and a long-term relationship entered into, there have been a number of problems regarding the mechanics and logistics of the agreement – some
have been local in nature and others as a result of global influences – all of which have been beyond our control.
We had hoped that the funding would be received by today and indicated as such in previous releases; the funding has now been delayed a further month and we have been given assurances that this deadline will be met.
The Board is, naturally, disappointed but we remain positive that the process for FDA approval can start in the very near future. As soon as we have any news we will issue a further statement.
Venice, Florida
June 30th, 2015
https://www.otcmarkets.com/ajax/showNewsReleaseDocumentById.pdf?id=15659
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM